MoonLake Immunotherapeutics Insider Trading Activity
Every SEC Form 4 insider transaction reported for MoonLake Immunotherapeutics (MLTX), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are MLTX insiders buying or selling?
In the last 12 months, MoonLake Immunotherapeutics insiders reported 1 open-market purchase ($98.8K) and 16 sales ($83.0M) — net selling of $82.9M. Since October 2020, Trabud has recorded 36 Form 4 filings for MLTX: 9 buys ($134.8M) and 27 sells ($268.0M).
Source: SEC EDGAR Form 4
Key Statistics (October 2020 – Jul 29, 2026)
Total Form 4 filings
36
SEC EDGAR
Insider filers
8
Insider buys (9)
$134.8M
Insider sells (27)
$268.0M
Insider sentiment
Net sellingNet insider flow of $133.1M in net selling since October 2020, and $82.9M in net selling over the last 12 months.
Recent MLTX insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jul 29, 2026 | Kristian Reich | Chief Scientific Officer | Sale | 1.1K | $20.00 | $22.0K | SEC ↗ |
| Jul 23, 2026 | Kristian Reich | Chief Scientific Officer | Sale | 52.4K | $20.02 | $1.0M | SEC ↗ |
| Jul 21, 2026 | Kristian Reich | Chief Scientific Officer | Sale | 43.7K | $20.09 | $877.9K | SEC ↗ |
| Jul 20, 2026 | Kristian Reich | Chief Scientific Officer | Sale | 16.1K | $20.01 | $322.3K | SEC ↗ |
| Jul 13, 2026 | da Silva Jorge Santos | Chief Executive Officer | Sale | 102.2K | $20.02 | $2.0M | SEC ↗ |
| Jul 2, 2026 | da Silva Jorge Santos | Chief Executive Officer | Sale | 47.8K | $20.03 | $956.9K | SEC ↗ |
| Jun 23, 2026 | Matthias Bodenstedt | Chief Financial Officer | Sale | 39.1K | $22.04 | $862.2K | SEC ↗ |
| Jun 18, 2026 | Matthias Bodenstedt | Chief Financial Officer | Sale | 17.9K | $19.67 | $351.6K | SEC ↗ |
| Jun 17, 2026 | Kristian Reich | Chief Scientific Officer | Sale | 150.0K | $19.01 | $2.9M | SEC ↗ |
| May 13, 2026 | Matthias Bodenstedt | Chief Financial Officer | Sale | 13.7K | $20.02 | $273.3K | SEC ↗ |
| Apr 16, 2026 | Matthias Bodenstedt | Chief Financial Officer | Sale | 2.4K | $19.56 | $47.5K | SEC ↗ |
| Apr 14, 2026 | da Silva Jorge Santos | Chief Executive Officer | Sale | 150.0K | $18.35 | $2.8M | SEC ↗ |
| Apr 10, 2026 | Matthias Bodenstedt | Chief Financial Officer | Sale | 87.8K | $18.95 | $1.7M | SEC ↗ |
| Apr 2, 2026 | Mark N Lampert | Director, 10% Owner | Sale | 3.8M | $16.79 | $63.0M | SEC ↗ |
| Dec 10, 2025 | da Silva Jorge Santos | Chief Executive Officer | Sale | 200.0K | $14.87 | $3.0M | SEC ↗ |
| Dec 10, 2025 | Kristian Reich | Chief Scientific Officer | Sale | 202.9K | $14.85 | $3.0M | SEC ↗ |
| Oct 9, 2025 | Matthias Bodenstedt | Chief Financial Officer | Purchase | 10.9K | $9.09 | $98.8K | SEC ↗ |
| Oct 1, 2025 | Bihua Chen | Other | Sale | 6.5M | $7.21 | $46.9M | SEC ↗ |
| Jul 7, 2025 | Catherine Moukheibir | Director | Sale | 23.5K | $48.79 | $1.1M | SEC ↗ |
| Oct 8, 2024 | Mark N Lampert | Director, 10% Owner | Sale | 2.0M | $50.00 | $100.0M | SEC ↗ |
| Oct 8, 2024 | Simon Sturge | Director | Sale | 171.0K | $53.72 | $9.2M | SEC ↗ |
| Mar 1, 2024 | da Silva Jorge Santos | Chief Executive Officer | Sale | 123.6K | $55.03 | $6.8M | SEC ↗ |
| Mar 1, 2024 | Kristian Reich | Chief Scientific Officer | Sale | 118.9K | $55.00 | $6.5M | SEC ↗ |
| Feb 23, 2024 | da Silva Jorge Santos | Chief Executive Officer | Sale | 1.1K | $55.27 | $62.2K | SEC ↗ |
| Feb 22, 2024 | Kristian Reich | Chief Scientific Officer | Sale | 21.1K | $57.33 | $1.2M | SEC ↗ |
Showing the 25 most recent of 36 Form 4 filings for MoonLake Immunotherapeutics.
Most active MLTX insiders
- Kristian Reich9 filings
- Bihua Chen8 filings
- da Silva Jorge Santos7 filings
- Matthias Bodenstedt7 filings
- Mark N Lampert2 filings
Ask anything about MLTX insider activity
Use Trabud's AI agent to query MoonLake Immunotherapeutics's Form 4 history in plain English — "Show me MLTX CEO purchases this year" or compare it against any other ticker.
Open the AI agentMLTX insider trading FAQ
Are MoonLake Immunotherapeutics insiders buying or selling?
In the last 12 months, MoonLake Immunotherapeutics insiders reported 1 open-market purchase ($98.8K) and 16 sales ($83.0M) — net selling of $82.9M. Since October 2020, Trabud has recorded 36 Form 4 filings for MLTX: 9 buys ($134.8M) and 27 sells ($268.0M). Over the full record that is net selling of $133.1M.
How many insiders trade MLTX stock?
8 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for MoonLake Immunotherapeutics. The most recent filing was accepted on Jul 29, 2026.
Where does Trabud get MLTX insider trading data?
All MLTX insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.